

PSAPL1 Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP12400a

Product Information

Application	WB, FC, E
Primary Accession	Q6NUJ1
Other Accession	NP_001078851.1
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB31383
Calculated MW	56627
Antigen Region	130-158

Additional Information

Gene ID	768239
Other Names	Proactivator polypeptide-like 1, Saposin A-like, Saposin B-Val-like, Saposin B-like, Saposin C-like, Saposin D-like, PSAPL1
Target/Specificity	This PSAPL1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 130-158 amino acids from the N-terminal region of human PSAPL1.
Dilution	WB~~1:1000 FC~~1:10~50 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	PSAPL1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	PSAPL1
Function	May activate the lysosomal degradation of sphingolipids.
Cellular Location	Secreted.


Background

PSAPL1 may activate the lysosomal degradation of sphingolipids (By similarity).


References

Gerhard, D.S., et al. Genome Res. 14 (10B), 2121-2127 (2004) :

Images



PSAPL1 Antibody (N-term) (Cat. #AP12400a) western blot analysis in Jurkat cell line lysates (35ug/lane).This demonstrates the PSAPL1 antibody detected the PSAPL1 protein (arrow).



PSAPL1 Antibody (N-term) (Cat. #AP12400a) flow cytometric analysis of Jurkat cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated donkey-anti-rabbit secondary antibodies were used for the analysis.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.